Annette M Lim - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Annette M Lim

Showing results (41-50 of 44) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 44 results.

The New England Journal of Medicine|September 12, 2022

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.

Journal for Immunotherapy of Cancer|October 15, 2025

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.

The New England Journal of Medicine|June 5, 2018

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.

The New England Journal of Medicine|June 2, 2025

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.

Pageof 5

Search research articles

Showing results (41-50 of 44) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 44 results.

The New England Journal of Medicine|September 12, 2022

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.

Journal for Immunotherapy of Cancer|October 15, 2025

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.

The New England Journal of Medicine|June 5, 2018

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.

The New England Journal of Medicine|June 2, 2025

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.

Pageof 5